Manufacturing Considerations for Cell and Gene Therapies During COVID-19
FDA published guidance that includes risk-based recommendations for minimizing the potential transmission of COVID-19.
FDA published guidance for industry on Jan. 19, 2021 to provide manufacturers of cell and gene therapies (CGT) with risk-based recommendations for minimizing the potential transmission of COVID-19.The guidance supplements a previous guidance document published in June 2020.
The guidance discusses source materials from donors, including cells and/or tissues. It also discusses cell expansion in culture, viral reduction steps, and formulation. “In light of SARS-CoV-2, FDA recommends that CGT product manufacturers perform a risk assessment that identifies, evaluates, and mitigates factors that may allow for transmission of SARS-CoV-2 by CGT products. A description of the risk assessment and mitigation strategies should be included in the appropriate submission to FDA (e.g., investigational new drug application [IND], biologics license application [BLA], or master file),” FDA states in the guidance document.
Source: FDA
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
